Skip to main content
. Author manuscript; available in PMC: 2010 Jan 1.
Published in final edited form as: J Neurosci Res. 2009 Jan;87(1):86–95. doi: 10.1002/jnr.21836

Fig.2.

Fig.2

DETA-NONOate treatment upregulates Stromal cell-Derived Factor 1 (SDF1) and Angiopoietin 1 (Ang1) in the IBZ and increases neuroblast migration in the ischemic brain after middle cerebral artery occlusion (MCAo) in mice. A-D and F-I: doublecortin (DCX) immunostaining in sham control (A and F); sham + DETA-NONOate treatment (B and G); MCAo control (C and H); and MCAo + DETA-NONOate treatment (D and I) in the SVZ and IBZ, respectively. E and J: Quantitative data of DCX-immunoreactive neuroblasts in the SVZ (E) and IBZ (J). K-N and Q-T: SDF1 and Ang1 immunohistochemical expression in the IBZ in sham control (K and Q); sham + DETA-NONOate (L and R); MCAo control (M and S); and MCAo + DETA-NONOate treatment (N and T). O and U: Quantitative SDF1 (O) and Ang1 (U) immunostaining data. P and V: SDF1 (P) and Ang1 (V) gene expression measured by real time polymerase chain reaction (PCR). Bar in G = 50 μm; Bar in T = 200 μm.